Consio | $3,300,000 | (Jan 27, 2026)
Orbital(US) | $60,000,000 | (Jan 27, 2026)
Inferact | $150,000,000 | (Jan 27, 2026)
Certified by Founder
Lodge
Umoja Biopharma
start up
United States
- Seattle, Washington
- 21/01/2025
- Series C
- $100,000,000
Umoja is developing a new approach to cancer therapy that retools a patient’s immune system in vivo, enhancing the body’s natural capacity to fight cancer. We envision a world where all patients have access to the most advanced immunotherapies and are free from the burdens of traditional cancer therapies
- Industry Biotechnology Research
- Website https://www.umoja-biopharma.com/
- LinkedIn https://www.linkedin.com/company/umoja-biopharma/
Related People
Andy ScharenbergFounder
United States -
Seattle, Washington
Physician, Scientist, Entrepreneur, passionate about the impact that CAR T-cells can have on the treatment of cancer.
Visitt | $22,000,000 | (Jan 27, 2026)
Cashmere(US) | $5,000,000 | (Jan 27, 2026)
Barnwell Bio | $6,000,000 | (Jan 27, 2026)
Mine(US) | $14,000,000 | (Jan 27, 2026)
Lucend | $3,300,000 | (Jan 27, 2026)
Standard Nuclear | $140,000,000 | (Jan 27, 2026)
Yuki | $6,000,000 | (Jan 23, 2026)
Allocation Strategy | $2,164,392 | (Jan 23, 2026)
Mia Labs | $20,000,000 | (Jan 23, 2026)